On August 21, Ding Lixin ,the Deputy Secretary of the Party Working Committee and the Director of the Management Committee of Suzhou Industrial Park, , and Ni Qian, the Deputy Director, led a delegation from the Science and Information Bureau of the Park, the Science and Education Innovation Zone and the Biomedical Innovation Centre visited Innolcon Medical Technology (suzhou) co., Ltd., Gezhi Biotechnology Co., Ltd., and Huaerkang Medical Technology (Suzhou) Co., Ltd . After listening to the reports, they fully affirmed the achievements, the strength of scientific research and innovation and the development status of the three companies.

       At the beginning of the meeting, Mr. Liu Shouguo, the co-founder, investor and also Chairman of Innolcon ,introduced his views of the current and future biomedical field and high-end medical device field, as well as his ideas on incubation of the medical industry over the years. Mr. Liu also announced a good news in the field of Ultrasonic therapy field in China -- Innolcon's "Ultrasonic Surgical System" obtained NMPA certification of Class III medical device(the first domestic brand for 5mm vessel sealing and cutting), marking a milestone in the performance of domestic ultrasonic scalpel.

       In the discussion, three CEOs introduced their companies in detail respectively:

       Innolcon was founded in 2014 and focused on the development and innovation of ultrasonic surgical system and ophthalmic surgical equipment. It has a first-class research and development team and core technology of ultrasonic surgical system. Innolcon has applied for more than 50 patents , obtained CE Certification in August 2019 and was the first Chinese brand obtaining 5mm vessel sealing and cutting NMPA certification comparable to the standard of international major companies in August, 2020, which indicates that Innolcon Medical has officially connected with the international community in the field of ultrasound therapy technology innovation.

 

       Gezhi Biotechnology is a high-tech biotech company co-founded by a number of overseas experts, returnee scientists and veterans of China’s domestic medical industry. It is committed to developing macromolecular immune anti-cancer new drugs through protein engineering, improving working mechanism of first-line anti-cancer drugs , increasing their specificity and reducing their toxicity. At present, a number of phage-based fully synthetic multi-domain antibody platforms are being established methodically.

 

       Huaerkang is committed to the research and development of robotic systems for abdominal surgery. The project includes three to four robots, a range of surgical instruments, endoscopic system, doctor's master console, robotic mobile console and hospital bed with remote control, remote diagnosis and AI analysis capabilities.

       After learning the basics of each company's R&D team, core technology, and future vision, Director Ding fully affirmed their innovative technology and research spirit, and expressed his expectations for future development. He hoped that the company would further benchmark itself against international top-class, increase investment in research and development, improve product competitiveness on high standards, and accelerate development.